Association Between Advanced TNM Stages and Increased Risk of Cardiac Dysfunction in Patients with LVEF < 50%

Medicina, Journal Year: 2025, Volume and Issue: 61(2), P. 301 - 301

Published: Feb. 10, 2025

Background and Objectives: Cardio-oncology addresses the growing concern of cardiovascular complications arising from cancer therapies. Although treatments have greatly enhanced survival outcomes, they frequently carry substantial risks to health. This research examines toxicity associated with HER2-targeted therapies, focusing on interconnection between tumor characteristics, including histopathological profiles TNM classification, development complications. The objective is identify key correlations that inform better prevention management strategies for cardiotoxicity in oncology patients. Materials Methods: retrospective study analyzed patients undergoing cytostatic treatments, particularly anthracyclines, radiotherapy, Cardiac function was monitored using echocardiographic assessments, global longitudinal strain left ventricular ejection fraction (LVEF). Patients were stratified based staging findings evaluate treatment regimens outcomes. Results: analysis revealed a significant association advanced stages reduced LVEF, stage T4 showing highest prevalence cardiac dysfunction. Cytostatic such as anthracyclines identified contributors cardiotoxicity, advanced-stage These emphasize importance regular monitoring detect early signs pre-existing risk factors demonstrated higher Conclusions: highlights need personalized approaches tailored cardioprotective improve outcomes enhance quality life Future studies should prioritize developing improved reduce linked contemporary treatments.

Language: Английский

---

Revolutionising Cardio-Oncology Care with Precision Genomics

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 2052 - 2052

Published: Feb. 26, 2025

Cardiovascular disease is the worldwide leading cause of mortality among survivors cancer due in part to cardiotoxicity anticancer therapies. This paper explores progress precision cardio-oncology, particularly genetic testing and therapeutics, its impact on cardiovascular diseases clinical laboratory settings. These advancements enable clinicians better assess risk, diagnose conditions, deliver personalised, cost-effective therapeutics. Through case studies cancer-therapy-related cardiac dysfunction, clonal haematopoiesis indeterminate potential, polygenic risk scoring, we demonstrate benefits incorporating genomics individualised care cardio-oncology. Furthermore, leveraging real-world genomic data settings can advance our understanding long noncoding RNAs microRNAs, which play important regulatory roles Additionally, employing human-induced pluripotent stem cells stratify guide prevention strategies represents a promising avenue for modelling While these showcase significant approaches, they also raise substantial ethical, legal, societal concerns. Regulatory oversight technologies should therefore evolve suitably keep up with rapid technology analysis. Provider education crucial appropriate use new applications, including existing protection available patients regarding information. provide confidence diverse study groups looking develop comprehensive effective applications heterogeneous populations. In settings, implementation within electronic medical records offer point-of-care decision support, thus providing timely information management decisions.

Language: Английский

---

Cardiovascular implications of anti-angiogenic therapeutic agents in cancer patients

American Heart Journal Plus Cardiology Research and Practice, Journal Year: 2024, Volume and Issue: 43, P. 100406 - 100406

Published: May 23, 2024

Language: Английский

---

Monoclonal Antibody Therapies in Cancer Immunotherapy

Advances in medical diagnosis, treatment, and care (AMDTC) book series, Journal Year: 2024, Volume and Issue: unknown, P. 419 - 472

Published: Aug. 28, 2024

Monoclonal antibodies (mAbs) can significantly improve patient outcomes in cancer treatment while reducing related side effects, offering a targeted therapy alternative to traditional regimens. This chapter describes the development, mechanisms, and applications of mAb therapies as critical components immunotherapy. The covers history progression use mAbs therapy, their multiple mechanisms—such immune checkpoint inhibitors, acumen for antigens antibody—drug conjugates—and newest developments this area. Moreover, reviews relevant case studies trial data compare impact these agents on various malignancies. concludes with summary current challenges—developed resistance, one hand—and toxic e.g., cytokine release syndrome neurotoxicity, other—and prospective avenues field.

Language: Английский

---

Cardiotoxicity in Breast Cancer: Impact of Clinical Classifications and Treatment on Heart Health

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4281 - 4281

Published: Dec. 23, 2024

Background/Objectives: Cardio-oncology has become essential in addressing cardiovascular complications from cancer therapies. While advancements treatments have improved survival rates, they also increase risks. This study evaluates the cardiotoxic effects of cytostatic treatments, examining relationship between tumor characteristics, such as histopathology and TNM classification, complications, aiming to improve cardiotoxicity prevention management oncology patients. Methods: We conducted a retrospective analysis patients treated with anthracyclines, HER2-targeted therapies, radiotherapy. Cardiac function was monitored via echocardiography, focusing on global longitudinal strain left ventricular ejection fraction (LVEF). troponins natriuretic peptides were measured detect subclinical cardiotoxicity, stratified by stage histopathology. Results: Our identified significant association certain anthracyclines reduction LVEF, particularly advanced-stage cancer. Biomarker assessments indicated early signs before clinical symptoms emerged. The findings demonstrated higher prevalence pre-existing risk factors. Conclusions: highlights importance personalized treatment protocols minimizing improving quality life for Regular cardiac monitoring, combined use biomarkers, can help identify high-risk early, allowing timely interventions. Future research should focus optimizing cardioprotective strategies mitigate risks associated modern Clinical Trial Registration: N/A (retrospective study).

Language: Английский

---